ArticleAmerican journal of respiratory and critical care medicine2023
IL-33 Expression Is Lower in Current Smokers at both Transcriptomic and Protein Levels.
Open access · hybridAbstract read
In one paragraph
Article in American journal of respiratory and critical care medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 30 citations in OpenAlex.
- A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4.The European respiratory journal · 2025Trial
- Type 2-low Asthma: Epidemiology, Multiomics, and Emerging Therapies.Current allergy and asthma reports · 2026Review
- Phase III LUNA clinical programme: design of four randomised, double-blind, placebo-controlled studies assessing the efficacy and safety of tozorakimab in patients with symptomatic COPD and a high risk of exacerbations.BMJ open respiratory research · 2026Article
- Mast cells and endothelial cells mediate interleukin-33 and ST2 responses in distal chronic obstructive pulmonary disease lungs.American journal of respiratory and critical care medicine · 2026Article
- Nuclear protein 1 is a cell death regulator in primary human airway epithelial cells and reduced in idiopathic pulmonary fibrosis.Scientific reports · 2026Article
- Temporal variation in markers of immune signaling and wound repair in primary human airway epithelial cells following acute versus repeated woodsmoke condensate exposure.Toxicological sciences : an official journal of the Society of Toxicology · 2026Article
- Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities.Nature reviews. Drug discovery · 2026Review
- Convergent death programs in chronic obstructive pulmonary disease: how pyroptotic and ferroptotic crosstalk reshapes therapeutic paradigms.Frontiers in immunology · 2026Review
- Beyond the alarm: unveiling the multifaceted role of IL-33 in kidney disease.Frontiers in immunology · 2026Review
- Beyond Blood Eosinophils: Target-Tier Heterogeneity and Patient Enrichment in COPD Type 2 Inflammation.Journal of inflammation research · 2026Review
- Article
- A translational view of airway epithelial dysfunction in COPD.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Chronic Obstructive Pulmonary Disease (COPD): Developments in Pharmacological Treatments.Drugs · 2025Review
- ILC2 Diversity, Location, and Function in Pulmonary Disease.Immunological reviews · 2025Review
- Article
- Life-threatening risk factors contribute to the development of diseases with the highest mortality through the induction of regulated necrotic cell death.Cell death & disease · 2025Review
- Innate Immunity and Asthma Exacerbations: Insights From Human Models.Immunological reviews · 2025Review
- ERS Congress 2024: highlights from the Airway Diseases Assembly.ERJ open research · 2025Article
- Integrative network pharmacology, transcriptomics, and microbiomics elucidate the therapeutic mechanism ofFrontiers in microbiology · 2025Article
- Established and Emerging Biological Therapies for the Treatment of Comorbid Asthma and Chronic Obstructive Pulmonary Disease.Journal of inflammation research · 2025Review
Corrections and comments
- Commented on by
Authors and funding
31 authors at 12 institutions in 7 countries.
Alen FaizRespiratory Bioinformatics and Molecular Biology, School of Life Sciences, University of Technology Sydney, Sydney, New South Wales, Australia.ORCID 0000-0003-1740-3538
Rashad M MahbubRespiratory Bioinformatics and Molecular Biology, School of Life Sciences, University of Technology Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-5055-9553
Fia Sabrina BoedijonoRespiratory Bioinformatics and Molecular Biology, School of Life Sciences, University of Technology Sydney, Sydney, New South Wales, Australia.
Milan I TomassenGroningen Research Institute for Asthma and COPD.
Wierd KooistraGroningen Research Institute for Asthma and COPD.
Wim TimensGroningen Research Institute for Asthma and COPD.
Martijn NawijnGroningen Research Institute for Asthma and COPD.
Philip M HansbroCentre for Inflammation, Faculty of Science, Centenary Institute and University of Technology Sydney, Sydney, New South Wales, Australia.
Matt D JohansenCentre for Inflammation, Faculty of Science, Centenary Institute and University of Technology Sydney, Sydney, New South Wales, Australia.
Simon D PouwelsGroningen Research Institute for Asthma and COPD.ORCID 0000-0001-7345-8061
Irene H HeijinkGroningen Research Institute for Asthma and COPD.
Florian MassipCentre for Computational Biology, Mines ParisTech, Paris Sciences et Lettres Research University, Paris, France.
Maria Stella de BiaseBerlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Roland F SchwarzBerlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Ian M AdcockNational Heart & Lung Institute, Imperial College London, London, United Kingdom.ORCID 0000-0003-2101-8843
Kian F ChungNational Heart & Lung Institute, Imperial College London, London, United Kingdom.
Anne van der DoesDepartment of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands.
Pieter S HiemstraDepartment of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands.
Helene GoulaouicSanofi, Chilly-Mazarin, France.
Heming XingSanofi, Chilly-Mazarin, France.
Raolat AbdulaiSanofi, Cambridge, Massachusetts.
Emanuele de RinaldisSanofi, Cambridge, Massachusetts.
Danen CunoosamySanofi, Cambridge, Massachusetts.
Sivan HarelRegeneron Pharmaceuticals, Tarrytown, New York.
David LedererRegeneron Pharmaceuticals, Tarrytown, New York.
Michael C NivensRegeneron Pharmaceuticals, Tarrytown, New York.
Peter A WarkCentre for Asthma & Respiratory Disease, The University of Newcastle, Newcastle, New South Wales, Australia; and.ORCID 0000-0001-5676-6126
Huib A M KerstjensGroningen Research Institute for Asthma and COPD.
Machteld N HylkemaGroningen Research Institute for Asthma and COPD.
Corry-Anke BrandsmaGroningen Research Institute for Asthma and COPD.
Maarten van den BergeGroningen Research Institute for Asthma and COPD.
University Medical Center Groningen · NLUniversity of Technology Sydney · AUInstitute for Asthma and Allergy · USRegeneron (United States) · USSanofi (United States) · USImperial College London · GBLeiden University Medical Center · NLSanofi (France) · FRHunter Medical Research Institute · AUMax Delbrück Center · DEParisTech · FRUniversity of Cologne · DE
Funding
Sanofi
Abstract
PubMed holds no abstract for this paper.
Indexed as
Pulmonary Disease, Chronic ObstructiveSmokersGene Expression ProfilingHumansInterleukin-33SmokingInterleukin-33basal cellcigarette smokeCOPDgene expressionIL-33
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.